D
Dermatologikum Hamburg | Hamburg, Germany
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Upadacitinib
TAK-279
AMG 451
Enbrel
LY3375880
Dupilumab
Rocatinlimab
5-FU
CHS-0214
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 13 total trials
Recently updated
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...
Active, not recruiting
Plaque Psoriasis
Drug: TAK-279
Drug: Placebo
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...
Enrolling
Plaque Psoriasis
Drug: TAK-279
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab
Trial sponsors
C
H
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems